EA202192346A1 - DELIVERY OF -SARCOGLICAN USING A VECTOR BASED ON ADENO ASSOCIATED VIRUS AND TREATMENT OF MUSCULAR DYSTROPHY - Google Patents

DELIVERY OF -SARCOGLICAN USING A VECTOR BASED ON ADENO ASSOCIATED VIRUS AND TREATMENT OF MUSCULAR DYSTROPHY

Info

Publication number
EA202192346A1
EA202192346A1 EA202192346A EA202192346A EA202192346A1 EA 202192346 A1 EA202192346 A1 EA 202192346A1 EA 202192346 A EA202192346 A EA 202192346A EA 202192346 A EA202192346 A EA 202192346A EA 202192346 A1 EA202192346 A1 EA 202192346A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
muscular dystrophy
sarcoglican
delivery
associated virus
Prior art date
Application number
EA202192346A
Other languages
Russian (ru)
Inventor
Луиза Родино-Клапак
Джерри Р. Менделл
Original Assignee
Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал filed Critical Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал
Priority claimed from PCT/US2020/019892 external-priority patent/WO2020176614A1/en
Publication of EA202192346A1 publication Critical patent/EA202192346A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Описаны способы лечения мышечной дистрофии, включающие введение вектора рекомбинантного AAV (rAAV) scAAVrh74.MHCK7.hSGCB, способы экспрессии гена бета-саркогликана у пациента, фармацевтические композиции, содержащие rAAV, и способы получения rAAV.Methods for the treatment of muscular dystrophy are described, including the introduction of the recombinant AAV (rAAV) vector scAAVrh74.MHCK7.hSGCB, methods for expressing the beta-sarcoglycan gene in a patient, pharmaceutical compositions containing rAAV, and methods for producing rAAV.

EA202192346A 2019-10-04 2020-02-26 DELIVERY OF -SARCOGLICAN USING A VECTOR BASED ON ADENO ASSOCIATED VIRUS AND TREATMENT OF MUSCULAR DYSTROPHY EA202192346A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962910779P 2019-10-04 2019-10-04
PCT/US2020/019892 WO2020176614A1 (en) 2019-02-26 2020-02-26 Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
EA202192346A1 true EA202192346A1 (en) 2021-12-07

Family

ID=80631179

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192346A EA202192346A1 (en) 2019-10-04 2020-02-26 DELIVERY OF -SARCOGLICAN USING A VECTOR BASED ON ADENO ASSOCIATED VIRUS AND TREATMENT OF MUSCULAR DYSTROPHY

Country Status (1)

Country Link
EA (1) EA202192346A1 (en)

Similar Documents

Publication Publication Date Title
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
WO2019079496A3 (en) Fully-human post-translationally modified antibody therapeutics
PH12020550706A1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
MX2021006646A (en) Recombinant adeno-associated viral vector for gene delivery.
PH12018502387A1 (en) Adeno-associated virus variant capsids and methods of use thereof
PH12021551341A1 (en) Compositions for drg-specific reduction of transgene expression
MX2021012867A (en) Fully-human post-translationally modified antibody therapeutics.
MX2021005517A (en) Gene therapy for neuronal ceroid lipofuscinoses.
MX2017012097A (en) Adeno-associated virus variants and methods of use thereof.
MX2022003857A (en) Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy.
MX2021010356A (en) Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy.
PH12020551096A1 (en) A modified raav capsid protein for gene therapy
MX2021012311A (en) Variant aav capsids for intravitreal delivery.
MX2021009696A (en) Gene therapy vectors for treatment of danon disease.
MX2022016332A (en) Adeno-associated virus vector delivery for muscular dystrophies.
MX2022004352A (en) Adeno-associated viral vectors for treatment of niemann-pick disease type c.
MX2022000551A (en) Modified aav capsid proteins for treatment of arthritic disease.
EA202192346A1 (en) DELIVERY OF -SARCOGLICAN USING A VECTOR BASED ON ADENO ASSOCIATED VIRUS AND TREATMENT OF MUSCULAR DYSTROPHY
MX2022013963A (en) Cross-species compatible adeno-associated virus compositions and methods of use thereof.
BR112022003142A2 (en) Alpha-sarcoglycan adeno-associated virus vector delivery and muscular dystrophy treatment
MX2023002569A (en) Systemic delivery of adeno-associated virus vector expressing g-sarcoglycan and the treatment of muscular dystrophy.
AR118192A1 (en) ADMINISTRATION OF b-SARCOGLICAN WITH A VECTOR OF ADENO-ASSOCIATED VIRUS AND TREATMENT OF MUSCULAR DYSTROPHY
EA202090957A1 (en) THERAPEUTIC AGENTS BASED ON FULLY HUMAN POST-TRANSLATION MODIFIED ANTIBODIES
TW202426017A (en) Pharmaceutical composition of non-enveloped virus
EA201892338A1 (en) DELIVERY OF MICRODISTROPHINE BY THE VECTOR ON THE BASIS OF THE ADENOASSOCIATED VIRUS FOR THE TREATMENT OF MUSCULAR DYSTROPHY